Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers Identify Protein Key in Proliferation of Lymphoma Cells

Published: Thursday, November 29, 2012
Last Updated: Wednesday, November 28, 2012
Bookmark and Share
Inhibiting PERK protein could reduce formation of cancerous tumors.

A team of researchers from UCSF and the University of Pennsylvania has uncovered how a normal biological mechanism called the “unfolded protein response,” goes awry in human lymphoma - work that may lead to the development of specific drugs to fight different forms of cancer.

The unfolded protein response is something of a safety self-destruct valve - it protects against the potential toxicity of unfolded proteins by causing cells in which they accumulate to harmlessly implode. But during the development of lymphoma, it can also cause cells to proliferate.

Led by Davide Ruggero, PhD, a UCSF associate professor of urology, and Constantinos Koumenis, PhD, from the Perelman School of Medicine at the University of Pennsylvania, the team showed how the unfolded protein response works in patients with human lymphomas and mice genetically bred to develop lymphomas. Instead of pushing the cancer cells toward self-destruction, it nudges them toward survival.

The work, described in an article published online recently by the Journal of Clinical Investigation, provides researchers with potential new targets for new drugs to fight cancer.

Specifically, they identified a human protein called PERK, which plays a central role in unfolded protein response. They showed that inhibiting PERK reduces the formation of tumors.

The research team also uncovered a main contributor to PERK activation: the activity of a cancer-related gene called c-Myc, which paradoxically switches on both cell proliferation and death. When the cell becomes cancerous, c-Myc–induced death is bypassed, promoting tumor formation.

“A critical feature of c-Myc-overexpressing cells is an increased rate of protein synthesis that is essential for Myc’s ability to cause cancer,” says Tom Cunningham, PhD, a postdoctoral fellow in the Ruggero lab.

“Myc tumor cells use this aberrant production of proteins to block apoptosis [programmed cell death] and activate the unfolded protein response. These cancer cells depend on Myc-induced increases in protein abundance to survive,” said Ruggero.

Targeting protein synthesis downstream of Myc oncogenic activity may represent a promising new therapeutic window for cancer treatment, he added.

PERK is already an active target for drug design in academia and the pharmaceutical industry, but any drugs that are developed against it will have to undergo clinical trials for safety and effectiveness before they are approved by the U.S. Food and Drug Administration and commonly available as human patient therapies.

“Although data from our lab and other groups suggest that PERK inhibition in tumors grown in animals is feasible, other studies suggest that PERK plays a critical role in the function of secretory tissues such as the pancreas,” said Koumenis.

Koumenis continued, “Carefully testing the effects of new PERK inhibitors in animal models of lymphoma and other malignancies in the next couple of years should address this question and could open the way for new clinical trials with such agents.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
Wednesday, October 26, 2016
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Tuesday, October 25, 2016
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Friday, September 30, 2016
NASA's DNA Sequencing in Space is a Success
DNA has been sequenced in space for the first time ever for the Biomolecule Sequencer investigation, using the MinION sequencing device.
Wednesday, August 31, 2016
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Friday, August 26, 2016
Immune-Cell Population Predicts Immunotherapy Response in Melanoma
All patients with high levels of one immune-cell type responded to treatment.
Tuesday, August 16, 2016
Gene Variant Explains Differences in Diabetes Drug Response
International precision medicine study advances understanding of the biology of Metformin.
Thursday, August 11, 2016
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Friday, May 27, 2016
Tense Tumours Lead to Poorer Prognosis
UCSF researchers have discovered that the chances of survival for patients with pancreatic adenocarcinoma (PDAC) — the most common type of pancreatic cancer — may depend in part on how tense their tumors are.
Tuesday, April 19, 2016
Gene Behind Rare Childhood Syndrome Identified
Online activism by one patient’s mother spurred research collaboration which led to the identification of a new genetic syndrome.
Friday, April 15, 2016
UCSF Immunologist to Head New Parker Institute for Cancer Immunotherapy
Renowned UC San Francisco immunologist Jeffrey Bluestone, PhD, has been named president and CEO of the Parker Institute for Cancer Immunotherapy, a national initiative launched with a $250 million grant from The Parker Foundation.
Thursday, April 14, 2016
How The Bat Got Its Wings
Finding may provide clues to human limb development and malformations.
Wednesday, March 30, 2016
How Early Childhood Vaccination Reduces Leukemia Risk
Chronic infections push ‘pre-leukemia’ cells, common in newborns, into malignancy.
Thursday, May 21, 2015
Environmental Carcinogens Leave Distinctive Genetic Imprints in Tumors
Chemically induced tumors bear ‘smoking gun’ traces that sharply differentiate them from genetically engineered cancers.
Thursday, November 06, 2014
Supreme Court Rules That Human Genes Can’t Be Patented
Most agree that the ruling reduces barriers to genetic testing and enables scientists to further genetic research and share data aimed ultimately at preventing and curing disease.
Friday, June 14, 2013
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Gene Editing Yields Tomatoes That Ripen Weeks Earlier
Research team develop method to make tomato plants flower and ripen fruit two weeks faster than current growth rates.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Unexpected Role for Epigenetic Enzymes in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Genetic Links to Brain Cancer Cell Growth
Researchers discover clues to tumour behaviour from genetic differences between brain cancer cells and normal tissue cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!